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Summary
Numerous functional studies have implicated PARL in relation to type 2 diabetes (T2D). We hypothesised that conflicting
human association studies may be due to neighbouring causal variants being in linkage disequilibrium (LD) with PARL.
We conducted a comprehensive candidate gene study of the extended LD genomic region that includes PARL and
transporter ABCC5 using three data sets (two European and one African American), in relation to healthy glycaemic
variation, visceral fat accumulation and T2D disease.
We observed no evidence for previously reported T2D association with Val262Leu or PARL using array and
fine-map genomic and expression data. By contrast, we observed strong evidence of T2D association with ABCC5
(intron 26) for European and African American samples (P = 3E−07) and with ABCC5 adipose expression in Europeans
[odds ratio (OR) = 3.8, P = 2E−04]. The genomic location estimate for the ABCC5 functional variant, associated with
all phenotypes and expression data (P = 1E−11), was identical for all samples (at Chr3q 185,136 kb B36), indicating that
the risk variant is an expression quantitative trait locus (eQTL) with increased expression conferring risk of disease. That
the association with T2D is observed in populations of disparate ancestry suggests the variant is a ubiquitous risk factor
for T2D.
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Introduction
Genome-wide association (GWA) studies have identified over
60 loci that are associated with type 2 diabetes (T2D) (Mor-
ris et al., 2012; Visscher et al., 2012) consistent with the
theory of polygenic inheritance (Clayton, 2009; Yang et al.,
2010; Visscher et al., 2012). One candidate gene not pre-
viously identified in human GWA studies is mitochondrial
gene PARL, located at 3q27 with a documented functional,
but controversial role in the development of T2D (Walder
et al., 2005; Fawcett et al., 2006; Powell et al., 2008; Hatu-
nic et al., 2009; Tang et al., 2009; Civitarese et al., 2010).
There is also replicated evidence of linkage to the 3q26-29
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locus region for glycaemic traits (Kissebah et al., 2000), obe-
sity (El-Sayed Moustafa & Froguel, 2013) and T2D (Hegele
et al., 1999; Vionnet et al., 2000; Francke et al., 2001; Bus-
field et al., 2002; Mori et al., 2002; Guan et al., 2008), but
these studies potentially implicate many genes in the region
(Pritchard & Cox, 2002).
Walder et al. (2005) demonstrated that skeletal muscle
PARL expression is reduced in insulin resistant and T2D-
induced desert sand rats, but could be restored again by in-
creased exercise. The study also showed a positive linear cor-
relation between PARL mRNA levels and insulin sensitivity
in humans and a nonsynonymous single nucleotide polymor-
phism or SNP (Val262Leu; rs3732581) in exon 7 of PARL
to be associated with fasting insulin. While there is sugges-
tive evidence of association with earlier age of T2D diagnosis
(Hatunic et al., 2009), the SNP-insulin association has not
subsequently been replicated (Fawcett et al., 2006; Powell
et al., 2008; Hatunic et al., 2009). Other studies have also
shown reduced PARL expression and mitochondrial function
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to be associated with T2D and ageing (Tang et al., 2009;
Civitarese et al., 2010; Curran et al., 2010).
Despite such functional evidence, PARL (and genes in the
immediate vicinity of PARL) have not been implicated with
T2D in the most recent association meta-analysis of 27 case-
control cohorts totalling 22,669 cases and 58,119 controls of
primarily European descent or with fasting insulin and glucose
levels for up to 133,010 nondiabetic individuals (Morris et al.,
2012).
The aims of this study are: (1) to assess if the previously re-
ported PARL missense Val262Leu polymorphism (not geno-
typed on commercial arrays) is associated with population
fasting plasma insulin levels and (2) to conduct a comprehen-
sive T2D candidate gene association and functional expression
study of the linkage disequilibrium (LD) region (approxi-
mately 185,000–185,250 kb, Build 36) that includes PARL
and neighbouring ABCC5.
Methods
Subjects and Data
To address these aims, we investigated the gene region by
requesting the genotype and phenotype data from two pub-
licly available data sets and collected additional fine map and
expression data from TwinsUK, since our method requires
original, rather than summary published data. All genomic
data were screened for quality control and tested for popula-
tion stratification using standard procedures (Balding, 2006)
for the following samples:
1. The Wellcome Trust Case Control Consortium
(WTCCC, phase I) T2D cases (n = 1926) and controls
(n = 2938), genotyped using the Affymetrix GeneChip
500K chip (Wellcome Trust Case Control Consortium,
2007).
2. The African American (AA) T2D case-control data were
obtained from the National Institute for Diabetes and
Digestive and Kidney disease (NIDDK) with cases (n =
1033, controls= 971) affected by T2D and end-stage renal
disease (ESRD) recruited from dialysis centres in North
Carolina and neighbouring states (Palmer et al., 2012).
Genotyping was performed on the Affymetrix Genome-
wide Human SNP array 6.0 (1 million SNPs).
3. A population-based sample of European twins (Twin-
sUK) (Moayyeri et al., 2013) using most recent measure
of fasting plasma insulin (pmol/l) and glucose (mmol/l),
a validated Dual-energy X-ray absorptiometry (DEXA)
based measure of visceral fat (Direk et al., 2013) and self-
reported T2D. Ten-hour fasting plasma insulin measures
were taken using a chemiluminesence assay (Roche 2010
analyser, pmol/ml). Glucose was measured using a Roche
P800 modular system. Fasting glucose and insulin lev-
els were mean-corrected for year of visit, age and sex
(R2 = 0.18 and R2 = 0.07, respectively). We used the
quantile normalised fasting plasma insulin: glucose ratio
(IGR), in order to have one summary glucose homeosta-
sis measure for analysis that was comparable with previous
studies (Kissebah et al., 2000). Homeostasis Model As-
sessment 2 (HOMA2) values were also calculated (Levy
et al., 1998) to assess beta cell function and insulin sensi-
tivity in relation to adipose gene expression results. T2D
status for TwinsUK data was ascertained via an online
questionnaire, asking if a physician had ever diagnosed
the individual with the condition, with approximately 5%
identified as T2D (n = 256/5616 respondents).
We used genomic TwinsUK data measured using the Il-
lumina HumanHap 610 Quad 610K array. The Val262Leu
(rs3732581) SNP was not included on the 610K commer-
cial array (n = 2300) and was therefore genotyped for a total
of 3087 twin samples. For TwinsUK samples with available
Illumina 610K SNP data, an additional 26 fine-map SNPs
were genotyped across the analytical window with a wide
range of minor allele frequencies (MAF  0.05) to improve
fine-mapping genotype coverage for the PARL and ABCC5
genes. Additional markers were selected using highly infor-
mative European LD genetic maps generated using publically
available HapMap CEU 2.5 million SNP data (see LD maps)
on the basis of where gaps on the 610K array were identified
in relation to the genetic map.
Subcutaneous adipose fat, lymphoblastoid cell line (LCL)
and skin messenger RNA levels were measured using the
Illumina expression array HumanHT-12 version 3 for 821
twins by the MuTHER consortium with data generation and
normalisationmethods described elsewhere (Grundberg et al.,
2012). Table S1 lists the six expression probe locations for
PARL and ABCC5, with probes marking different isoforms
for each of these genes. Only adipose tissue probes were used
for the expression analysis, as we reasoned LCL and skin
expression are unlikely to be relevant to the aetiology of T2D.
Statistical Genetic Methods
Biometric model
For the candidate marker Val262Leu test of association, fast-
ing insulin, glucose, IGR and T2D were regressed upon the
Val262Leu SNP (rs3732581 G/G was coded as 0, G/C as
1 and C/C as 2) using mixed linear regression methods. A
previously reported interaction model (Walder et al., 2005)
testing for association between fasting insulin levels and age
stratified by Val262Leu genotypes was also assessed.
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LD maps and genetic association
The association analyses for this study utilise high-resolution
genetic maps with locations expressed in LD Units (LDU
map), which were recently also used to identify 200 genes
for Crohn’s disease (Elding et al., 2013). The LDU map
and association mapping method are both based upon the
Male´cot model of decline of association with genetic distance
in LDU (Maniatis et al., 2002; Wellcome Trust Case Con-
trol Consortium, 2007). Once the population-specific ge-
netic maps have been estimated, an extension of the Male´cot
model can then be used to implement a multimarker test
of association (Maniatis, 2007) utilising information from all
markers in a region simultaneously to obtain a location esti-
mate for the functional common variant (Sˆ) associated with
the phenotype (±standard error of the genetic location). For
this study, a physical analytical window of 800 kb (184,743–
185,548 kb) was used that corresponds to approximately 10
LDU on the genetic map for the European samples and 17
LDU for the AAs. The 800 kb analytical window included
a total of 22 genes (KLHL6, KLHL24, YEATS2, MAP6D1,
PARL,ABCC5,HTR3D,HTR3E,EIF2B5,DVL3,AP2M1,
ABCF3, VWA5B2, MIR1224, ALG3, ECE2, CAMK2N2,
PSMD2, EIF4G1, SNORD66, FAM131A and CLCN2) lo-
cated within this region, with the entire region assessed as
part of one single Male´cot test of association.
The construction of the LDU maps using the HapMap
Phase II data and association mapping methods used for this
study are described in detail elsewhere (Collins, 2007). All
analyses used genomic human reference sequence March
2006 (National Center for Biotechnology Information Build
36.1, hg18).
eQTL regression analyses
For each expression probe (three per gene), we tested for
evidence of regulatory eQTLs for PARL and ABCC5 adipose
tissue expression using the same Male´cot modelling approach
and analytical window as described above, controlling for
recorded experimental batch effects by analysing regression
residuals. Mixed linear regression models were also used to
test if the phenotypes of insulin resistance (IGR), visceral fat
accumulation and T2D were associated with adipose gene
expression for the twin samples.
Significance thresholds
Despite being a candidate gene association study, we used a
stringent genome-wide significance threshold of 1E−05 for
the genetic association analyses. This conservative threshold
corresponds to independent tests for 4800 analytical LDU
windows that cover the entire human genome (0.05/5000;
α = 1E−05) (Elding et al., 2013).
For the phenotype-expression association analyses, we used
regression methods (Camp & Farnham, 2001) to estimate
Table 1 Nonsynonymous SNP rs3732581 (Val262Leu) test of asso-
ciation with fasting plasma insulin levels and type 2 diabetes (T2D)
for TwinsUK data.
Fasting insulin T2D
Beta SE P-value OR SE P-value
Panel A: Main effect model
rs3732581 −0.17 0.56 0.95 0.82 0.12 0.10
AgeALL 0.12 3.E−02 1.E−04 1.04 0.01 3.E−08
Panel B: Interaction model (SNP-Age)
AgeGG 0.13 0.06 0.03 1.03 0.01 2.E−07
AgeGC/CC 0.12 0.04 1.E−03 1.05 0.01 3.E−09
Panel A (Main effect model): association between pheno-
type and SNP rs3732581 adjusted for age. Increased fasting in-
sulin levels and risk of T2D are positively associated with age,
but are not associated with Val262Leu. Panel B (Interaction
model): association between phenotype and age stratified by SNP
using an interaction model (adapted from Walder et al., 2005).
For the TwinsUK data, the postestimation Wald test contrast-
ing two regression coefficient interaction terms provides no ev-
idence that association between phenotype and age differs be-
tween homozygous GG and GC/CC individuals (i.e. βGG =
βGC/CC = βALL, see main text). Fasting plasma insulin levels are
measured in pmol/l. Year of blood sample collection was included
as a categorical confounding variable for both models. Sample sizes
were 2358 and 2895 for insulin and T2D analyses, respectively.
that the six probes correspond to the equivalent of four in-
dependent tests and that the five T2D-related phenotypes
correspond to three independent tests due to the correla-
tion structure between them. Therefore, for these analyses
we used a conservative Bonferroni correction of α = 1E−03
(0.05/(3×4)).
Results
Val262Leu (rs3732581, PARL Exon 7) as a
Candidate SNP for Insulin Resistance and T2D
Regression models confirmed a strong association between
risk of insulin resistance, T2D and age with both fasting in-
sulin levels (0.12 pmol/l per year) and risk of T2D [odds ratio
(OR) = 1.04 per year] increasing with age (Table 1, Panel A).
By contrast, Val262Leu showed no evidence of association
(unadjusted or adjusted for age) with fasting plasma insulin
levels (P = 0.95) or self-reported T2D (P = 0.10). We also
assessed a previously suggested model by Walder et al. (2005)
for an age-by-Val262Leu genotype interaction effect (Table 1,
Panel B) for fasting insulin and T2D. Although both genotype
groups showed a positive association between fasting insulin
levels and age and T2D and age, GG individuals showed no
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Figure 1 LD plot illustrating the degree of linkage
disequilbrium in the PARL/ABCC5 region. Pairwise marker
LD (Dʹ) plotted for TwinsUK data for 122 SNPs in the 200 kb
gene region (185,020–185,220 kb, Build 36). PARL includes
SNP markers rs3732581 (Val262Leu, exon 7) and rs3792588
(promotor region) and ABCC5 includes rs4912515 (intron 26,
in closest proximity to the association model functional variant
location estimate) with these three SNP locations highlighted as
blue stars.
evidence of stronger association between phenotype and age
compared to CC/GC individuals, with a Wald χ21 of 0.14
(P = 0.71) and 0.74 (P = 0.39) for fasting insulin and T2D,
respectively (Table 1).
LD in the PARL/ABCC5 Gene Region
Figures 1 and 2 illustrate the high degree of LD within and
moderate LD between the PARL and ABCC5 genes. Fig-
ure 1 plots pairwise LD (D) and Figure 2 plots more infor-
mative fine scale genetic maps for HapMap European (CEU,
European Americans) and African (ASW, African ancestry in
Southwest USA) populations in the form of cumulative LDU
(see Methods section). Note that while there is breakdown
in LD between the two genes, there still remains some ev-
idence of extended LD between the two. By plotting the
genetic LDU maps against physical distance (kb), the nonlin-
ear relationship is revealed as a “Block-Step” structure (See
Fig. 2). “Blocks” of LD represent areas of low haplotype di-
versity, while “Steps” define LD breakdown, mainly caused
by recombination. It is this high-resolution LD information
that is used to locate potential functional variants associated
with fasting insulin and glucose plasma levels and T2D for
European and AA samples.
The PARL/ABCC5 Gene Region as a Candidate
for Insulin Resistance and T2D
Table 2 presents the evidence for phenotypic association with
genomic polymorphism data centred on the PARL/ABCC5
gene region for European and AA populations. TheWTCCC
T2D sample provided significant evidence of association
(P = 3E−06) with a functional variant location estimate Sˆ
at 185,136 kb.
An identical location estimate for the functional variant was
obtained for AA T2D case-control data with an Sˆ location at
185,137 kb with nominal significance (P = 0.01). The result
was replicated for Europeans (TwinsUK) measured for IGR
(P = 0.04) with the same location estimate as T2D at ABCC5
intron 26 (185,136 kb). Meta-analysis of the three genomic
result P-values (Table 2, WTCCC P = 3E−06, NIDDK
P = 0.01 and TwinsUK 610K P = 0.04) using Fisher’s method
(Fisher, 1925), provided overall significant evidence of associ-
ation (P = 3E−07) for a common functional variant located
at 185,136 kb with 95% confidence intervals (CIs) for this lo-
cation ranging from 185,108 to 185,235 kb. The CI includes
the ABCC5 gene, promoter and 3’ region (ABCC5 gene
co-ordinates: 185,120–185,215 kb), but excludes neighbour-
ing PARL. The functional variant location estimate (arrowed
line) and 95% CIs (dotted lines) are illustrated in Figure 2.
This result implicates ABCC5, but also excludes the remain-
ing 21 genes located within this gene rich region (see Meth-
ods for gene list) as being candidate disease susceptibility loci
for T2D.
In relation to why previous GWA studies have not pre-
viously identified ABCC5 as a T2D susceptibility gene, it is
worth noting that while individual nominally significant SNP
p-values nearest to the estimated ABCC5 variant location at
185,136 kb for the WTCCC (e.g. rs3749441, P = 1E−03),
NIDDK (e.g. rs1016752, P = 0.04) and TwinsUK samples
(e.g. rs8180093, P = 0.002) do not pass genome-wide sig-
nificance (α = 1E−05), when all the SNPs in the region are
considered collectively as part of a multilocus model, they do
provide strong evidence of association with T2D and insulin
resistance (meta-analysis P = 3E−07). The two nominally
significant WTCCC SNPs (marked ×) nearest the Sˆ location
estimate in Figure 2 (arrow) are rs3749441 and rs3792582.
eQTL Analyses
Table 2 presents the results for one adipose expression probe
measured for the TwinsUK samples, which provides strong
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Figure 2 African and European genetic maps and scatter plot for WTCCC association between type 2 diabetes and single
nucleotide polymorphisms. The graph presents a line plot for African (red) and European (blue) cumulative linkage disequilibria
unit genetic maps (Y1-axis, LDU) and scatter plot for WTCCC type 2 diabetes association with SNPs in the PARL/ABCC5
gene region (Y2-axis, −log10P). The genetic maps for HapMap Africans (ASW, Phase III) and Europeans (CEU, Phase II) are
plotted with each dot representing an SNP location for the high-resolution HapMap samples from which these
population-specific genetic maps are inferred. The arrowed vertical line labelled Sˆ represents the functional variant location
estimate and the dotted lines, the 95% CI for the variant location. The total genetic distance (Y1-axis) for the same physical
genomic region (X-axis) is greater for the African population compared to the European population, reflecting older ancestry
and a greater number of historical recombination events for this population.
Table 2 Phenotype-genotype multi-marker association for PARL/ABCC5 gene region in Europeans and African Americans.
n
Sˆ (kb) Gene
Data Phenotype Data Sample SNP P-value location 95% CI (transcript strand)
Genomic T2D WTCCC 4864 83 3.E−06 185,136 185,108 185,215 intron 26 ABCC5 (−)
Genomic T2D NIDDK 2004 104 0.01 185,137 185,114 185,218 intron 26 ABCC5 (−)
Genomic IGR TwinsUK 610 2300 176 0.04 185,136 185,110 185,235 intron 26 ABCC5 (−)
Genomic meta-analysis
(3 samples):
1.E−07 185,136 185,108 185,235 intron 26 ABCC5 (−)
Fat expression: ABCC5 mRNA TwinsUK 700 202 1.E−11 185,136 185,109 185,235 intron 26 ABCC5 (−)
All three samples show statistical evidence of association between T2D, IGR and ABCC5 with a common causal variant estimated to
most likely be located in intron 26. All samples provide exactly the same functional variant Sˆ location at or close to 185,136 kb (95% CI
185,108–185,235 kb, B36). Abbreviations: IGR, fasting insulin: glucose serum ratio levels, NIDDK, National Institute for Diabetes, Digestive
and Kidney disease, T2D, type 2 diabetes, WTCCC, Wellcome Trust Case Control Consortium.
evidence of genetic association (P = 1E−011) with an iden-
tical location estimate Sˆ at ABCC5 intron 26 (185,136 kb,
95%CI 185,109–185,235 kb). The remaining five adipose ex-
pression probes for ABCC5 and PARL showed no evidence
of eQTLs for the same analytical window (using threshold
α = 1E−03, data not shown). This indicates that the asso-
ciated functional variant in ABCC5 is both associated with
T2D and regulates ABCC5 transcript expression.
Additional analyses show that the ABCC5 Ilmn_1706531
probe for all tissues is consistently and significantly correlated
with all three PARL probes (Table S2) indicating that PARL
and ABCC5 are co-expressed.
Adipose ABCC5 Expression is Positively
Associated with Fasting Insulin, Visceral Fat
Accumulation and T2D
We performed a series of analyses regressing T2D and T2D-
related phenotypes upon each adipose probe in turn, using a
mixed linear regression model to control for batch and age ef-
fects. Visceral fat was included as a T2D-related phenotype as
this trait has previously been shown to be strongly associated
with T2D and arguably may play a causal role in T2D disease
onset (Direk et al., 2013). In particular, we were interested in
adipose probe Ilmn_1706531 as this probe already showed
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evidence of eQTL genetic association with the longest
ABCC5 transcript (Table 2).
The univariate regression results (Table 3A) indicate that
only ABCC5 adipose probe Ilmn_1706531 was significantly
associated with all phenotypes (HOMA2 β cell function,
HOMA2 peripheral sensitivity, fasting IGR, visceral fat accu-
mulation and T2D). Although PARL Ilmn_2257665 was also
nominally associated with visceral fat (P = 0.04) and T2D
(P = 0.01), these phenotypic associations appeared to be
driven by ABCC5 Ilmn_1706531 due to the observed neg-
ative correlation between the two probes (r = −0.38, Ta-
ble S2). When HOMA2 sensitivity, visceral fat and T2D
were regressed upon Ilmn_1706531, age, batch effects and
the relevant nominally significant probes (Ilmn_2257665,
Ilmn_1651964 and ILMN_2302358), only Ilmn_1706531 re-
mained significantly and strongly associated with each phe-
notype (Table 3B). This confirmed that only adipose probe
Ilmn_1706531 was independently associated with all five
T2D-related phenotypes. The strength of association for this
ABCC5 probe (Table 3B) was estimated to have a correlation
coefficient of +0.11 with HOMA2 β cell function (95% CI
0.04–0.17), −0.15 with HOMA2 peripheral sensitivity (95%
CI −0.07 to −0.22), 0.11 with IGR (95% CI 0.05–0.18), a
regression coefficient of 30 cm2 visceral fat per standard de-
viation (SD) increase in expression (95% CI 13.2–47.4; r =
0.19, 95% CI 0.12–0.17) and for T2D, an OR of 3.8 per SD
increase in probe expression (95% CI 1.25–11.6). In addition,
the prevalence of T2D is three times higher in subjects with
high ABCC5 expression compared to those with low expres-
sion (top vs. lowest expression quartile; 3% cf. 9%; χ23 = 13,
P = 0.005. However, note that for the 820 subjects with com-
plete measured adipose expression data, only 37 individuals
(4.5%) reported having T2D).
The association between IGR and adipose probe
Ilmn_1706531 was largely driven by fasting insulin (P =
1E−04) rather than glucose levels (P = 0.02) with raised adi-
pose ABCC5 transcript levels associated with increased β cell
function (Homeostasis Model Assessment HOMA2B, P =
1E−03) and reduced peripheral insulin sensitivity (HOMA2S,
P = 2E−04). Significantly, none of the mRNA probes
for LCL and skin tissues—including ABCC5 probe
Ilmn_1706531—were associated with phenotypes IGR, vis-
ceral fat or T2D (data not shown).
Discussion
In this study, we confirm that the nonsynonymous PARL
SNP rs3732581 (exon 7) and the PARL gene itself, show no
evidence of association with fasting plasma insulin and glu-
cose levels or T2D for European and AA samples. By contrast
however, for the first time we demonstrate that the neigh-
Figure 3 Diagram illustrating ABCC5 genetic and mRNA
association with intermediate phenotypes and type 2 diabetes. An
eQTL in ABCC5 (intron 26) regulates mRNA expression levels
and is associated with fasting plasma insulin and glucose levels,
visceral fat accumulation and T2D for TwinsUK data. ABCC5
transcript Ilmn_1706531 is also strongly associated with
intermediate phenotypes and T2D (see Table 3), suggesting the
causal mechanism of association is mediated via mRNA
expression that are tissue and transcript specific. Double-headed
arrows indicate correlation and curved lines association, but are
not directly causal.
bouring ABCC5 transporter gene shows replicated evidence
of genetic association with T2D and insulin resistance at the
same locus for three populations. The same variant observed
to be associated with T2D also plays a regulatory role in
controlling ABCC5 adipose expression levels, with elevated
ABCC5 expression levels in turn significantly associated with
reduced insulin peripheral sensitivity in nondiabetic individu-
als (r = −0.15), increased visceral fat accumulation (r = 0.19)
and increased risk of T2D (OR = 3.8, 95% CI 1.25–11.6),
all of which indicates that over expression of ABCC5 may be
causally implicated in T2D pathophysiology (see Fig. 3). By
contrast, PARL genetic variants and gene expression are not
associated with intermediate phenotypes or T2D for human
data, suggesting that previously observed animal and exper-
imental data for association between PARL dysfunction and
T2D may be a consequence rather than a cause of disease
onset.
The ABCC5 genetic variant may also explain contradic-
tory human association results observed for Val262Leu, if
previously observed association with PARL is in fact due to
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confounding LD with functional variants in ABCC5. For ex-
ample, SNPs such as rs4912515 (Fig. 1)—in immediate prox-
imity to the ABCC5 variant Sˆ location estimate—show sig-
nificant evidence of long-range LD with Val262Leu in PARL.
There are three major strengths to the genetic map–based
test of association that should be mentioned here. The first is
that this elegant model is highly interpretable, both in terms
of population genetic theory (Male´cot, 1948) and in the con-
text of association mapping (Maniatis et al., 2002; Wellcome
Trust Case Control Consortium, 2007). The second is that
the model is more sensitive than single SNP tests, which are
widely used in GWA studies, to detect functional variants that
are potentially associated with a combination of neighbouring
genotyped markers, but not necessarily in high LD with any
single genotyped marker. For the commercial SNP arrays that
are currently available [and when the assumption of high al-
lelic identity begins to breakdown (Pritchard & Cox, 2002)], a
multimarker approach provides a much more realistic scenario
than the current practice of assuming a putative functional
variant is in high LD with just one genotyped marker. Direct
estimation of the functional variant location (along with a lo-
cation 95% CI) provides more precise location inferences than
individual associated SNPs and provides a considerable degree
of commensurability between different commercial genotyp-
ing platforms that other methods do not. Thirdly, gene map-
ping is far more efficient using markers located upon a genetic
rather than a physical map (Maniatis, 2007).
How does the evidence from previous animal model and
functional studies for reduced PARL expression associated
with observed and induced T2D (Walder et al., 2005; Tang
et al., 2009; Civitarese et al., 2010), square with current
results for observed human genomic and expression data
implicating ABCC5, but not PARL? We believe the most
likely explanation for these observations is that ABCC5
plays a contributory causal role in T2D onset, while PARL
dysfunction appears to be a consequence rather than a cause
of insulin resistance and disease state. This view is supported
by (1) evidence for a functional genetic variant in ABCC5
associated with T2D in multiple human populations that
also regulates ABCC5 expression and (2) empirically, PARL
and ABCC5 mRNA transcripts appear to be co-expressed,
perhaps suggesting co-regulation of the two genes. ABCC5
may also (partly) drive the expression of PARL, since the
observed association between phenotype (T2D, visceral
fat accumulation) and PARL expression (Ilmn_2257665,
Table 3) is conditionally independent, once ABCC5
expression (Ilmn_1706531) is accounted for.
ABCC5 is a member of the ATP-binding cassette trans-
porter superfamily (Dean & Allikmets, 2001), transporting
cyclic nucleotides such as cyclic guanosine monophosphate
(cGMP) (Jedlitschky et al., 2000), where cGMP is a common
regulator of ion channel conductance, glycogenolysis and cel-
lular apoptosis. Although ABC transporter genes including
ABCC5 have been studied in relation to cancer treatment
and drug resistance (Wijnholds et al., 2000; Tamaki et al.,
2011), little is known about ABCC5 in relation to T2D. One
exception to this is an ABC transporter expression study of
uptake and efflux transporters in the liver of rats with induced
diabetes (streptozotocin injection). The study demonstrates
that liver ABCC5 (MRP5) protein expression levels (Western
blot) in diabetic rats fed high-fat diets collapse (to 4%) when
compared to control rat liver expression levels (Nowicki et al.,
2008).
This study supports the transporter gene superfamily as
worthy of further investigation in relation to common T2D
(Xiang & Xiao-Dong, 2009), with the subfamilies of ABCC
and ABCG already implicated in different ways (Matsuo,
2010). Mutations in the sulfonylurea receptor (SUR) 1 en-
coded by ABCC8 have previously been shown to cause
neonatal diabetes (Greeley et al., 2011), maturity onset di-
abetes of the young (MODY) (Bowman et al., 2012) and
adult T2D (Tarasov et al., 2008). In addition, the ABCG
transporter genes have also been implicated in cholesterol
transport in animal models of T2D (Levy et al., 2010).
A key question raised by this study is the nature of any po-
tential functional relationship between PARL and ABCC5.
Future work will need to include efforts to identify the func-
tional variant (for example a regulatory element in intron 26)
and undertake further functional studies such as cell culture
work to more clearly establish the molecular mechanisms by
which ABCC5 confers risk of T2D.
In conclusion, the ABCC5 polymorphism is associated
with T2D in three populations of European and African an-
cestry and is observed to regulate ABCC5 expression levels
in healthy middle-aged Europeans. ABCC5 expression lev-
els are in turn associated with insulin resistance, visceral fat
accumulation and disease. The fact that ABCC5 is a trans-
porter protein with ABCC transporters prioritised for drug
research (Hillgren et al., 2013) may also provide additional
opportunities for drug target development in the treatment
of T2D.
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